{"id":"ganovo-ritonavir-interferon-nebulization","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances (nausea, diarrhea)"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Interferon-related flu-like symptoms"},{"rate":null,"effect":"Hyperuricemia"}]},"_chembl":{"chemblId":"CHEMBL2108506","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ganovo acts as a nucleoside analog that inhibits viral RNA-dependent RNA polymerase, while ritonavir enhances bioavailability by inhibiting cytochrome P450 metabolism. Interferon nebulization provides direct pulmonary immune stimulation and antiviral activity at the site of infection, particularly relevant for respiratory viral infections.","oneSentence":"This combination therapy uses Ganovo (an antiviral nucleoside analog) with ritonavir (a protease inhibitor booster) and optional interferon nebulization to inhibit viral replication and enhance immune response.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:31:04.611Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 (based on institutional use at Ninth Hospital of Nanchang)"},{"name":"Severe respiratory viral infections"}]},"trialDetails":[{"nctId":"NCT04291729","phase":"PHASE4","title":"Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection","status":"COMPLETED","sponsor":"The Ninth Hospital of Nanchang","startDate":"2020-02-17","conditions":"COVID-19","enrollment":11}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":43,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ganovo+ritonavir+/-Interferon nebulization","genericName":"Ganovo+ritonavir+/-Interferon nebulization","companyName":"The Ninth Hospital of Nanchang","companyId":"the-ninth-hospital-of-nanchang","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy uses Ganovo (an antiviral nucleoside analog) with ritonavir (a protease inhibitor booster) and optional interferon nebulization to inhibit viral replication and enhance immune response. Used for COVID-19 (based on institutional use at Ninth Hospital of Nanchang), Severe respiratory viral infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}